证券代码： 002020 证券简称：京新药业 编号：2018001 浙江京新药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中泰证券池陈森、上海中金资本孙智超、东云阿尔法基金杨 | | 人员姓名 | 梦朝 | | | 时间 | 2018 年 3 月 13 | 日 | | 地点 | | 浙江京新药股份有限公司新昌总部董秘办公室 | | 上市公司接待人 | | | | 员 | | 董事会秘书金志平、证券事务代表张波 | | 投资者关系活动 | 1 | 、介绍公司基本业务情况和未来发展规划。 ...

证券代码： 002020 证券简称：京新药业 编号：2017001 浙江京新药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 方正证券陈家华、长城证券赵浩然、华创证券孙渊、国信证 | | 人员姓名 | 瑞锐投资陆慧 | 券梁佳、马来西亚投资胡梦宇、日兴资产管理公司杜毅忠、 | | | | | | 时间 | 2017 年 11 月 14 | 日 | | 地点 | 浙江京新药股份有限公司杭州总部 | | | 上市公司接待人 | | 董事会秘书（代）金志平、证券事务代表张波 | | ...

证券代码： 002020 证券简称：京新药业 编号：2019002 浙江京新药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 兴业证券赵垒、招商证券李点典、国联安基金焦阳、敦和资 | | 人员姓名 | | 产叶施、广东民营投资王勇、枫润资产龚星宇 | | 时间 | 2019 年 5 月 13 | 日 | | 地点 | | 浙江京新药股份有限公司杭州总部贵宾会议室 | | 上市公司接待人 员 | | 董事会秘书金志平、证券事务代表张波 | | 投资者关系活动 | 1 | 、介绍公司基本 ...

证券代码： 002020 证券简称：京新药业 编号：2019001 浙江京新药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中泰证券池陈森、中泰证券资管周旭驰、永诚资产邓韵阳、 | | 人员姓名 | 资产王申、通用投资陈佳琦 | 上海森锦投资季亮、开源证券陈明、双安资产马振军、银湖 | | 时间 | 2019 年 5 月 8 日 | | | 地点 | | 浙江京新药股份有限公司杭州总部贵宾会议室 | | 上市公司接待人 员 | 证券事务代表张波 | | | 投资者关系活动 ...

证券代码： 002020 证券简称：京新药业 编号：2018002 浙江京新药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 广发证券吴文华、国投瑞银王鹏、前海人寿王安艺、基石资 | | 人员姓名 | 本朱筱姗 | | | 时间 | 2018 年 11 月 6 | 日 | | 地点 | | 浙江京新药股份有限公司新昌总部行政楼会议室 | | 上市公司接待人 员 | | 董事会秘书金志平、证券事务代表张波 | | 投资者关系活动 | 1 | 、介绍公司基本业务情况和未来发展规划。 | ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-----------------------|-------------------------------|---------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | 循远投资覃婷；广发资管徐默凡；海通自营胡幸；恒远资本李 | | 参与单位名称及 | | 婧；歌斐资产沈芃泽；野村资管张熙；圆信永丰方瑾；国泰君 安李子波；华泰资管李勇剑；凯石吴蔽野；兴业证券胡储辉； | | 人员姓名 | | 国信证券资管隋欣；东海自营施杨扬；国泰基金邱晓旭；中融 ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | 兴业证券胡储辉、林莹，财通证券华挺，东吴证券于彦秋，博 道基金邓韵阳，中航信托谢天，深圳国诚投资张妃珺、相健、 | | | | | | 参与单位名称及 人员姓名 | 杨海 ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-----------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | 中航信托戴佳敏，泰康资产王晓峰，观富（北京）资产杨洁， | | | | 光大资产徐德仁，富国基金姜恩铸，新疆前海联合基金张宇煊， | | | | ...

1 股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | --- | --- | |----------------|-------------|-------------------------------------|------------------------------|--------|-------|---------------------| | | | | | | | | | | | √特定对象调研 □分析师会议 | | | | | | | | □媒体采访 □业绩说明会 | | | | | | 投资者关系活动 | □新闻发布会 | | □路演活动 | | | | | 类别 | □现场参观 | | | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | | | 闫庚威 太平基金 许睿 富安达 | | | | | | | | 方瑾 圆信永丰 鲍冲 中信建投资管 | | | | | | | | | | | | | | | | 邱晓旭 兴全基金 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 927.29 million, an increase of 11.01% compared to CNY 835.31 million in the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was CNY 174.70 million, reflecting a growth of 9.66% from CNY 159.31 million year-on-year[6]. - The net cash flow from operating activities for the year-to-date period was CNY 446.51 million, up 16.46% from CNY 384.99 million in the previous year[6]. - The company's basic earnings per share remained stable at CNY 0.20, with a diluted earnings per share also at CNY 0.20[6]. - The company reported a net profit margin improvement, with net profit for the period increasing due to higher revenue and controlled costs[25]. - The net profit for the current period is 475,470,952.50, an increase from 440,185,520.85 in the previous period, representing a growth of approximately 8%[27]. - Operating profit for the current period is 533,943,335.85, compared to 486,661,837.14 in the previous period, indicating an increase of about 10%[27]. - The total profit for the current period is 532,781,444.69, compared to 488,259,200.58 in the previous period, indicating an increase of about 9%[27]. Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 7,013.43 million, representing a 5.98% increase from CNY 6,617.70 million at the end of the previous year[6]. - The company's total liabilities reached ¥2,021,985,295.16, up from ¥1,639,127,704.24, reflecting an increase of 23.4%[22]. - The total equity attributable to shareholders was CNY 4,967.43 million, showing a slight increase of 0.18% from CNY 4,958.33 million in the previous year[6]. - The total equity attributable to shareholders was ¥4,967,428,026.10, a slight increase from ¥4,958,326,790.13[24]. Cash Flow - The net cash flow from operating activities surged by 382.27% to ¥681,416,066.30, driven by increased sales revenue and improved collection of accounts receivable[11]. - Cash flow from operating activities for the current period is 681,416,066.30, significantly up from 141,293,758.40 in the previous period, showing a substantial improvement[31]. - The net cash flow from investing activities is -617,421,539.09, a decrease from 277,295,528.25 in the previous period, indicating a negative trend[31]. - The net cash flow from financing activities is -181,848,325.22, compared to 81,552,926.87 in the previous period, reflecting a decline[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,299[15]. - The largest shareholder, Lü Gang, holds 20.77% of the shares, totaling 178,796,755 shares[15]. Operating Costs and Expenses - Total operating costs for the third quarter of 2022 were ¥2,300,367,857.99, up from ¥2,124,942,041.95, reflecting a year-over-year increase of 8.3%[25]. - Research and development expenses for the third quarter of 2022 amounted to ¥246,403,668.53, compared to ¥227,892,721.46 in the previous year, indicating an increase of 8.1%[25]. - The company's financial expenses decreased by 125.93% to -¥59,376,378.44, mainly due to increased interest income from time deposits and exchange gains[11]. - The company reported a 746.30% increase in non-operating expenses to ¥2,179,982.31, primarily due to an increase in bad debt write-offs[11]. Asset Composition - Current assets totaled ¥3,271,012,226.99 as of September 30, 2022, slightly down from ¥3,292,888,604.35 at the end of the previous year[22]. - Non-current assets increased to ¥3,742,419,718.96 from ¥3,324,808,506.47, marking a significant rise of 12.5%[22]. - Cash and cash equivalents decreased to ¥1,543,092,081.54 from ¥1,558,668,597.33, a decline of 1%[22]. - Cash and cash equivalents at the end of the period amount to 1,401,844,562.75, slightly up from 1,391,803,166.97 in the previous period[31].